On September 22, 2025, Imunon, Inc. (IMNN) announced the presentation of new translational data from the company's Phase 2 OVATION 2 trial of IMNN-001 in patients with newly diagnosed advanced ovarian cancer. The results were presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Ovarian Cancer Research. The data showed that there was a positive shift in the tumor microenvironment (TME) through decreased immunosuppressive cells (IDO+, PDL1+, Treg, CD4+) and increased immunostimulatory cells (CD8+, myeloid dendritic cells) in a majority of the patients' post-treatment. In addition, IMNN-001 treatment shifts the TME from "cold" to "hot" through increased recruitment of anti-tumor CD8+ and myeloid dendritic cells in 50-80% of the paired samples. The ongoing OVATION 3 trial currently has four trial sites activated with plans for additional sites to accelerate patient recruitment.
